StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
Back to screenerCompare

METROPOLIS — METROPOLIS HEALTHCARE LTD

Price History

Data as of 26 Jun 2026· via fincrux

How METROPOLIS has traded over time.

Is the price reasonable right now?

Where today's price sits within its own 12-month range — context, not advice.

Upper end of its 12-month range89% of range

Trading about 29% above its 12-month low and near recent highs — historically pricier territory for this stock. It sits above its 200-day average, the longer-term trend.

₹421 low₹559 high
vs 50-day avg
+4.5%
vs 200-day avg
+10.8%
Beginner mode
Plain English, with everything explained

METROPOLIS

NSE

METROPOLIS HEALTHCARE LTD

Healthcare / Diagnostics

₹543.35
0.00%
last close
0%
Quality Score
A mixed pictureBig money selling

METROPOLIS HEALTHCARE LTD passes 1 of 3 checks. There's something to like here, but also a few things to be careful about. Read the four checks below before forming a view.

Company size
₹11514.00 Cr
Price tag
70.7×
Money it earns
13.1%

The four quality checks

Every company faces the same four checks. Tap the ? on any term to learn what it means.

01

Is the company drowning in loans?

We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.

Aligned

The company keeps its borrowing under control. That's a sign of a sturdy balance sheet.

D/E 0.11goal < 0.5
02

Does it make good money, consistently?

We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.

Watch

Profitability is decent but not quite at the level we'd call strong.

ROE 13.1%goal > 15% (3y avg)
03

Is the big, smart money buying in?

Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.

Watch

Big investors are roughly holding their position, neither rushing in nor out.

FII+DII 46.2%goal stable or rising (2Q)
04

Is the price reasonable right now?

Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.

No data

We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.

Data unavailablegoal P/E < 5y median

What we noticed

Observations from the data — not recommendations.

  • Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.
Data as of 26 Jun 2026· via fincrux

StockVault is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.

Balance Sheet

What METROPOLIS owns and owes over the years. Tap the ? on any line to learn what it means.

Line itemFigures in ₹ crore
ItemMar '22Mar '23Mar '24Mar '25Sep '25
Borrowings377268195178152
Equity Capital1010101010
Reserves8299261,0211,2341,317
Total Assets1,4591,4341,4731,6851,732
Total Liabilities1,4591,4341,4731,6851,732

Borrowings trending down

Total borrowings are down about 60% over the last 5 years — the company has been reducing its reliance on debt.

Periodic Performance

Yearly net profit for METROPOLIS — does it earn money consistently?

Potential turnaroundPotential turnaround (pattern in the data)

Profit dipped in the middle years and has been recovering in the most recent ones. That's a pattern in the data, not a forecast.

₹200 Cr
₹139 Cr
₹116 Cr
₹125 Cr
₹157 Cr
Mar '22Mar '23Mar '24Mar '25Mar '26
rev ₹1,157 Crrev ₹1,066 Crrev ₹1,103 Crrev ₹1,217 Crrev ₹1,365 Cr
Net profit · annualProfitLoss

Strengths & Risks

What the numbers say is good and bad about METROPOLIS — observations, not recommendations.

Strengths

2
  • Keeps borrowing low relative to its own capital — a sturdy balance sheet.
  • Recent results show a return to profit after weaker years — a turnaround pattern in the data.

Risks

2
  • Large professional investors have been trimming their stake recently.
  • Sits near the top of its 12-month range — historically pricier territory for this stock.

Institutional Ownership Trend

FII and DII holding across the last four quarters.

FII· Foreign institutions
10.4%-2.4 pp
DII· Domestic institutions
35.8%+3.4 pp
Jun '25Sep '25Dec '25Mar '26

Sector Peers

How others in Healthcare / Diagnostics score on the same four guardrails.

  • LALPATHLABDR. LAL PATH LABS LTD.69
View the full sector